Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II sintilimab + anlotinib for recurrent or metastatic head and neck squamous cell carcinoma after platinum failure
ChiCTR2200055602Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in head and neck squamous cell carcinoma (HNSCC), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Overall response rate. Started Jan 2022; status: recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2200055602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055602.